International Journal of Cardiology

Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-driven HART CVE Blood Test Highly Accurate for Predicting Major Cardiac Events in Patients with Chronic Kidney Disease

Retrieved on: 
목요일, 11월 3, 2022
Cardiology, Technology, Health, General Health, Health Technology, Research, Software, Artificial Intelligence, Hospitals, Science, Clinical Trials, American Heart Association, Public health, Company, Journal, HART, Arrest, Heart, Machine learning, Medicare, International Journal of Cardiology, CVE, AI, Congress, Chronic kidney disease, Principal, Biomarker, Open heart, Clinical Cardiology, Stroke, AUC, Algorithm, Centers for Disease Control and Prevention, Center, Massachusetts General Hospital, European Society of Cardiology, Canadian International Council, CKD, Artificial intelligence, The American Journal of Cardiology, Hospital, Kidney disease, Harvard Medical School, Risk, Cardiovascular disease, American College of Cardiology, AHA, Patient, MD, European Journal of Preventive Cardiology, Medical device, Cardiology, Medicine

Researchers from Massachusetts General Hospital tested 446 CKD patients undergoing coronary or peripheral angiography to predict two-year risk of heart attack, stroke, or cardiovascular death.

Key Points: 
  • Researchers from Massachusetts General Hospital tested 446 CKD patients undergoing coronary or peripheral angiography to predict two-year risk of heart attack, stroke, or cardiovascular death.
  • This accuracy across the different stages is important given a sharp increase in cardiovascular event risk as patients progressively decline in kidney function.
  • This HART CVE application is valuable for both hospitalized and outpatient chronic kidney patients.
  • In addition to the HART CVE test for risk of major cardiac events, Prevencio offers a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries.

Co-Author of the Karolinska 1000 Consecutive MANTA® Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

Retrieved on: 
목요일, 9월 15, 2022
Weck, Health, MANTA, Karolinska Institute, NYSE, Canadian International Council, SAFE, Anesthesia, VCDS, CRF, Percutaneous, Device, LMA, Interventional cardiology, TAVI, U.S. Securities and Exchange Commission, Patient, Emergency medicine, Karolinska University Hospital, Solution, Annual report, Clinical trial, Teleflex, VCD, International Journal of Cardiology, Security (finance), 1048, Observational study, GLOBE, Prostatic urethral lift, Urology, Catheter, Veni, vidi, vici, TFX, TCT, Radiology, MARVEL, Medical device, Medical imaging, Cardiology, Pilling, QuikClot

TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.

Key Points: 
  • TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.
  • The findings of our study indicate that the MANTA Device is easy to learn and has a short learning curve, which is in line with our user experience.
  • The MANTA Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.
  • Percutaneous plug-based vascular closure device in 1000 consecutive transfemoral transcatheter aortic valve implantations.

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

Retrieved on: 
수요일, 5월 18, 2022
Medical Devices, Health, General Health, Research, Cardiology, Science, Risk, Cardiomyopathy, International Journal of Cardiology, Sodium bicarbonate, Survival, US Foods, U.S. Securities and Exchange Commission, EDT, Heparin-induced thrombocytopenia, PCI, US FDA, Patient, Multimedia, ABMD, NASDAQ, Decompensation, US, Meta-analysis, Myocardial infarction, Canadian International Council, ASL, Mortality, Heart, Kidney, FDA, U.S. FDA, SCAI, Cardiogenic shock, Bleeding, Heparin, Pulmonary artery, SHOCK, Heart failure, Inferior vena cava, Registry, Lung, Society, Security (finance), PubMed, Cochrane, MD, Pharmaceutical industry, Medical device, Cardiology, Impella, Abiomed

The patients were divided into two groups those who received Impella support pre-PCI (n=2,970) and those who received Impella support during or post-PCI (n=3,840).

Key Points: 
  • The patients were divided into two groups those who received Impella support pre-PCI (n=2,970) and those who received Impella support during or post-PCI (n=3,840).
  • The data showed significantly reduced short-term mortality rates in AMICS patients who received Impella support pre-PCI, compared to those who received Impella support during or post-PCI (37.2% vs 53.6%, p=0.002).
  • Details of the presentation and the study abstract are available on the SCAI 2022 Scientific Sessions website .
  • SCAI also provides Abiomed an opportunity to highlight its latest FDA approval, which simplifies Impella management with the goal of improving patient outcomes.

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction

Retrieved on: 
화요일, 5월 10, 2022
Michael Faraday, Canadian International Council, Muscle, Mortality, Injury, GLOBE, Toxicity, Polaris Partners, Death, Oxygen, Heart failure, Safety, Food, Reperfusion injury, Patient, U.S. National STEMI Receiving Centers, Major, Fred Hutchinson Cancer Research Center, American Heart Association, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PCI, Marketing, MPH, Harvard Medical School, Sodium iodide, CEO, Heart, International Journal of Cardiology, Hydrogen peroxide, Disease, Pharmaceutical industry, Dietary supplement, STEMI, Brigham, Medicine, MD, Cardiology

The trial is being conducted under a Special Protocol Agreement reached with the U.S. Food and Drug Administration.

Key Points: 
  • The trial is being conducted under a Special Protocol Agreement reached with the U.S. Food and Drug Administration.
  • The first patient was enrolled by Dr. Jay Traverse, interventional cardiologist, and Jo Anne Goldman, at the Minneapolis Heart Institute Foundation in Minneapolis, MN.
  • This trial is a testament to Faradays commitment to finding innovative solutions to unmet needs that may enable patients to live longer, better lives.
  • With a clinically and commercially experienced senior leadership team, the company is focused on treating and preventing muscle injury.

WhiteSwell Adds Experienced Executives to its Senior Management Team

Retrieved on: 
수요일, 1월 26, 2022
Technology, Research, Medical Devices, Clinical Trials, Cardiology, Software, Hardware, Health, Science, Linda, University, Mechanical, Leadership, Canadian International Council, International Journal of Cardiology, Institute, Patient, Congestion, Mechanical engineering, Swelling, Nursing, Heart, VP, Engineer, HF, Clinical, Boston Scientific, National University of Ireland, Edema, Homeostasis, Integration, University of St. Thomas (Minnesota), National university, Diagnosis, Martin, Acute decompensated heart failure, Lymphatic system, Clinical trial, CEO, Tissue, Master of Engineering, Integrated assessment modelling, MBA, Hospital, Institution, Heart failure, Fatigue, Electronics, IDE, Pharmaceutical industry, Cardiology, ADHF, Medtronic, Science, the Lymphatic System and ADHF, WhiteSwell, THE LYMPHATIC SYSTEM AND ADHF, WHITESWELL

Linda joins WhiteSwell from Medtronic, where she directed numerous clinical research teams.

Key Points: 
  • Linda joins WhiteSwell from Medtronic, where she directed numerous clinical research teams.
  • She previously served as Vice President of Clinical Affairs at Respicardia, where she led successful execution of a randomized, pivotal IDE clinical trial.
  • Both Linda and Martin bring extensive experience and seasoned leadership to the WhiteSwell team, said Eamon Brady, CEO.
  • With a powerful senior management team in place, WhiteSwell is well positioned to advance its pioneering treatment of acute decompensated heart failure by leveraging the lymphatic system.

Healthy Extracts Launches High-Potency Organic Citrus Bergamot Formulations with Clinically Proven Heart Benefits, Available Exclusively on Amazon

Retrieved on: 
수요일, 10월 20, 2021
Triglyceride, Immune system, Risk, Metabolism, Woman, CDC, Krka (company), UBN, Private Securities Litigation Reform Act, Memory, Person, Blood pressure, News, Rosuvastatin, OTCQB, Flavonoid, Achievement, Canadian International Council, Cardiology, BPF, Ageing, Annual report, Ultimate Brain, Disease, The Non-GMO Project, Superfood, IP, Sale, FDA, Citrus, Stress (linguistics), GLOBE, Health, Polyphenol, Degenerative disease, Forward-looking statement, International Journal of Cardiology, SEC, Heart, Tablet, Cognition, Company, Perfume, Pharmaceutical industry, Dietary supplement, Fine chemical

LAS VEGAS, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, has launched two new high-potency natural formulations, Organic Citrus Bergamot for Women and Organic Citrus Bergamot , available today only on Amazon.

Key Points: 
  • LAS VEGAS, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, has launched two new high-potency natural formulations, Organic Citrus Bergamot for Women and Organic Citrus Bergamot , available today only on Amazon.
  • Offered exclusively in North America by Healthy Extracts, Citrus Bergamot SuperFruit has the highest quality and concentration of polyphenols and flavonoids (BPF).
  • Designed to be naturally effective for womens health, Organic Citrus Bergamot for Women contains highly concentrated citrus bergamot tablets with a daily dosage of 1,500 milligrams.
  • Organic Citrus Bergamot is suitable for anyone looking to improve their health and wellness by providing a daily dosage of 1,500 milligrams of Citrus Bergamot SuperFruit.